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Helicobacter pylori antibiotic resistance is increasing worldwide, emphasizing the urgent
need for more rapid resistance detection prior to the administration of H. pylori eradication
regimens. Macrolides and fluoroquinolones are widely used to treat H. pylori. In this study,
we aimed to compare the diagnostic performance of A) 23SrDNA qPCR (with melting
curve analysis) and an in-house developed gyrA qPCR followed by Sanger sequencing
with a commercial IVD-marked hybridization probe assay (for 23SrDNA and gyrA) using
142 gastric biopsies (skipping culturing) and B) the same two qPCR for 23SrDNA and
gyrA (including Sanger sequencing) with whole-genome sequencing (WGS) and
phenotypic characterization of clarithromycin and levofloxacin resistance using 76
cultured isolates. The sensitivity of both qPCRs was 100% compared to that of the
commercial IVD-marked hybridization probe assay for the detection of H. pylori in gastric
biopsies (without resistance testing). The specificity of the qPCR gyrA followed by Sanger
sequencing was 100%, indicating that the best sequence identity was always H. pylori.
The results show good agreement between molecular tests, especially between qPCR
(inclusive Sanger sequencing) and WGS. Discrepancies (concerning mutated or wild type
of positive H. pylori gastric biopsies) were observed between Sanger sequencing of the
gyrA gene and the corresponding commercial hybridization probe assay, mostly because
the high sequence diversity of the gyrA gene even at positions adjacent to the relevant
codons of 87 and 91 interfered with obtaining correct results from the hybridization probe
assay. Interestingly, we found several mixed sequences, indicating mixed populations in
the gastric biopsies (direct detection without culturing). There was a high percentage of
both levofloxacin and clarithromycin resistance in gastric biopsies (both between 22% and
29%, direct detection in gastric biopsies). Therefore, we recommend analyzing both
targets in parallel. We confirmed that phenotypic resistance is highly correlated with thegy | www.frontiersin.org December 2020 | Volume 10 | Article 5963711
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Frontiers in Cellular and Infection Microbioloassociated mutations. We concluded that the two qPCR followed by Sanger sequencing
of the gyrA gene is a fast, cost-effective and comprehensive method for resistance testing
of H. pylori directly in gastric biopsies.Keywords: Helicobacter pylori, direct detection in gastric biopsies, (quantitative) real-time PCR, phenotypic drug
resistance, 23S rDNA gene, gyrA, hybridization probesINTRODUCTION
Helicobacter pylori is a gram-negative bacterium that infects
approximately half of the human population worldwide. H.
pylori infection is a major determinator in the etiology of
various gastrointestinal diseases, including chronic active
gastritis, peptic or duodenal ulcers, gastric adenocarcinoma,
and mucosa-associated tissue lymphoma. Clarithromycin, in
combination with metronidazole or amoxicillin and a proton
pump inhibitor (Gisbert et al., 2000; Malfertheiner et al., 2017;
Marques et al., 2020), has been the key drug in the first-line H.
pylori eradication regimen for more than a decade. However, the
widespread use of clarithromycin has led to an increase in
clarithromycin-resistant H. pylori, diminishing the effectiveness
of conventional first-line treatment regimens and increasing
treatment fai lures due to drug-resis tant H. pylori
(Wueppenhorst et al., 2009; Buzás, 2010; Thung et al., 2016).
An increasing trend of clarithromycin resistance in H. pylori can
be observed worldwide and specifically in European countries,
with an overall primary clarithromycin resistance rate of 17%–
21% (de Francesco et al., 2010; Dolak et al., 2017; Bilgilier et al.,
2018). Although levofloxacin resistance has not been studied as
extensively, there is also a trend towards increasing primary and
secondary levofloxacin resistance in H. pylori (Hug and Rossi,
2001; Mandell et al., 2007). With rising antibiotic resistance rates,
the usefulness of the currently applied “test-and-treat” strategy is
questionable, emphasizing the need for rapid and accurate
diagnostics to assess drug resistance in H. pylori prior to the
administration of antibiotics.
Clarithromycin resistance in H. pylori is mainly attributable
to three single point mutations (A2146C, A2146G, and A2147G)
in the 23S rDNA (Zullo et al., 2007; Boyanova et al., 2010;
Mégraud, 2012; Saracino et al., 2012), while mutations in the
gyrase gene (gyrA; mainly at codons 87 and 91) are associated
with levofloxacin resistance (Boyanova et al., 2010). Despite
advances in H. pylori diagnostics, culture-based phenotypic
drug susceptibility testing (DST) is still the most commonly
applied method. However, the successful isolation and
cultivation of H. pylori from gastric biopsy specimens is a
challenging task hampered by a number of technical factors
(e.g., quality of the clinical specimen, occurrence of microbial
commensal flora, inappropriate transport conditions)
(Cuadrado-Lavıń et al., 2012). Furthermore, culture-based
methods require highly trained laboratory personnel and take
up to 14 days to obtain results. Rapid and accurate molecular
methods that can detect H. pylori and assess its drug resistance
are becoming increasingly important in diagnostics with rising
antibiotic resistance.gy | www.frontiersin.org 2Additionally, whole-genome sequencing (WGS) has been
successfully employed for the detection of mutations that result
in phenotypic drug resistance inH. pylori (Boyanova et al., 2010).
With advances in sequencing technology (e.g., affordable
instrument pricing, user friendly and simple workflows,
standardization of protocols, and reagents, reasonable per
sample costs), diagnostic laboratories can sequence culture
isolates in a clinically relevant timeframe (24 to 48 h),
providing a comprehensive view of the genotype and relevant
drug resistance mutations of a bacterial isolate (Redondo et al.,
2018; Lauener et al., 2019). However, a major remaining
limitation of WGS is that it is still mostly performed on
culture isolates, as the application of metagenomic approaches
directly to gastric biopsies are hampered by low bacterial DNA
content and high human DNA background (especially for DNA
extraction methods without the depletion of human DNA).
To date, there are only a few commercially available
molecular assays for the detection of mutations in the
23SrDNA (these tests are predominant) (e.g., LightMix
Modular Helicobacter 23S rDNA, Genotype HelicoDR) and
gyrA genes, and some in-house developed assays have been
published (Schabereiter-Gurtner et al., 2004; Cambau et al.,
2009; Bilgilier et al., 2018; Lauener et al., 2019; Makristathis
et al., 2019; Jehanne et al., 2020). Specifically, quantitative real-
time PCR assays (qPCR) combined with melting curve analysis
enable the timely assessment of H. pylori and its drug resistance
specimens (Schabereiter-Gurtner et al., 2004; Gazi et al., 2013;
Bénéjat et al., 2018, Redondo et al., 2018) however, published
data are limited to 23SrDNA. Design of a qPCR for gyrA remains
a complex challenge due to the high sequence variation of H.
pylori (Ailloud et al., 2019; Estibariz et al., 2019). To date and to
our knowledge, only Genotype HelicoDR (Cambau et al., 2009)
is used as a commercial test (with CE-IVD label) for the
combined detection of different mutations of 23SrDNA and
gyrA. However, this commercial kit is based on a time-
consuming non-realtime PCR followed by hybridization which
includes many incubation steps (Jehanne et al., 2020).
Additionally, hybridization probes based analysis of gyrA gene
(which have to differentiate between 1 bp sequence variation but
only at relevant codon 87 and 91) conflicts with the above-
mentioned extraordinary genetic diversity (Ailloud et al., 2019;
Estibariz et al., 2019).
The goals of this study are a comprehensive comparison of
different methods (culturing and molecular) in order to apply
qPCR for a timely and sensitive susceptibility testing of
clarithromycin as well as levofloxacin in parallel directly from
gastric biopsy without culturing (which is hampered by different
disadvantages). Especially for qPCR of gyrA, insufficient data areDecember 2020 | Volume 10 | Article 596371
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date data from central Europe of the direct molecular
susceptibility testing in gastric biopsies reveals a rather high
(both between 22% and 29%) percentage of resistance in
clarithromycin as well as levofloxacin resistance which might
be due to selection of suboptimal antibiotic treatment of patient
(Kenyon, 2019).MATERIALS AND METHODS
Clinical H. pylori Isolates and H. pylori
Culture
This study was conducted using a set of 76 H. pylori strains from
the bacterial strain collection of the Institute of Medical
Microbiology (IMM), University of Zurich. The H. pylori
strains were isolated between 2013 and 2017 from gastric
biopsy specimens that were sent to the IMM for culture-based
phenotypic DST. For this study, H. pylori strains were
intentionally selected based on their antimicrobial resistance
phenotype and are therefore, not representative of H. pylori
primary antibiotic resistance epidemiology in Switzerland. After
thawing, the strains were incubated on in-house produced
Brucella agar plates (with 5% horse blood) for 3 days at 37°C
under microaerobic conditions (90% N2, 5% CO2, 5% O2) using a
gas generator (CampyGen, Thermo Scientific, Waltham, MA,
USA). After 3 days, H. pylori isolates were subcultured on
Brucella agar plates to obtain sufficient biomass for the E Test®
(bioMérieux, Marcy l’Etoile, France) and to perform DNA
extraction for WGS.
Phenotypic DST by E-Test®
H. pylori cultures were adjusted to a McFarland standard of 3
(Yuen et al., 2005). A McFarland of 3 was chosen as H. pylori is a
fastidious bacterial pathogen, and sufficient growth is required
on the Müller Hinton fastidious (MHF) agar plates in order to
evaluate the E-Test results. In the diagnostic laboratory,
previously published protocol for phenotypic susceptibility
testing on fastidious organisms were considered (King, 2001).
Phenotypic DST was performed on MHF agar plates containing
5% horse blood (bioMérieux) using the following E-Tests®
(bioMérieux): clarithromycin (0.016–256 mg/L) and
levofloxacin (0.016–32 mg/L). Agar plates were incubated
under microaerobic conditions at 37°C for 3 days.
Subsequently, MICs were determined using a light microscope
(Leica M80, Leica Microsystems, Heerbrugg, Switzerland).
Susceptibility interpretation was performed according to the
guidelines of the European Committee on Antimicrobial
Susceptibility Testing (Redondo et al., 2018).
DNA Extraction, qPCR, and Melting Curve
Analysis
DNA was extracted from unmodified (i.e., without fixation or
embedment) gastric biopsy specimens (collected 2018) using the
QIAamp DNA Mini Kit (order number 51304, Qiagen, Hilden,
Germany) with proteinase K digestion, according to theFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 3manufacturer’s recommendations. Gastric biopsies had a
diameter of 1–3 mm and duration of proteinase K incubation
was at least 1h for complete dissolution. The clinical specimens
were from the clients (e.g., gastroenterologist) of Dr. Risch
diagnostic laboratory without any selections. DNA was
extracted from H. pylori isolates with the DNeasy® UltraClean®
Microbial Kit (Qiagen, Hilden, Germany), following the
manufacturer’s recommendations.
For qPCR amplification of 23S rDNA, extracted DNA was
added to a mixture consisting of Roche PCR-grade water (Roche,
Rotkreuz, Switzerland), LightCycler® DNA Multiplex Master
Mix (Roche), 0.25 µl of Uracil-DNA Glycosylase (Sigma
Aldrich, Switzerland) and LightMix® Modular Helicobacter
23S rDNA primers and probes (TIBMolbiol, Berlin, Germany).
We followed the qPCR Mastermix composition guidelines and
the amplification protocol provided by TIBMolbiol. The 23S
rDNA qPCR was performed on a LightCycler 480-II® (Roche)
followed by melting curve analysis.
For qPCR amplification of the gyrA gene, primers by
Fujimura et al. (2004) were used. In addition, new primers
were designed targeting the same primer binding sites, but
accommodating sequence variations found in clinical
specimens from different locations in Switzerland (customers
of CLM Dr Risch group). Four different forward primers, Hp
gyrA-f1 5’-CGATGCATGAATTAGGYCTTACT-3’, Hp gyrA-f5
5’-CGATGCATGAATTAGGCCTCACT-3’, Hp gyrA-f6 5’-
CGATGCATGAATTAGGGCTTACT-3’, and Hp gyrA-f8 5’-
CGATGCATGAATTAGGCCTTACC-3 ’ , and 2 reverse
primers, Hp gyrA-r 5’-TTCTTCACTCGCCTTRGTCAT-3’ and
Hp gyrA-r4 5’-TTCTTCGCTCGCTTTGGTCAT-3’, were
designed. For gyrA qPCR amplification, extracted DNA was
added to a mixture consisting of Roche PCR-grade water
(Roche), LightCycler® 480 SYBR Green I Mastermix (Roche),
0.25 µl of Uracil-DNA Glycosylase (Sigma Aldrich) and each
primer at a final concentration of 0.5 µM. GyrA qPCR was
performed on a LightCycler 480-II® instrument (Roche) with the
following cycler settings: 95°C for 10 min and 45 cycles of 95°C
for 10 s, 58°C for 10 s and 72°C for 20 s. Melting curve analysis
was performed from 60°C to 90°C with continuous detection.
The times at different temperatures were according to the
recommendations provided on the polymerase package insert.
Annealing temperatures (5 different temperatures between 57°C
and 66°C) were tested using the Vircell Amplirun Helicobacter
pylori DNA control (order number MBC049, distributed by
Ruwag, Bettlach, Switzerland). A melting curve was performed
after qPCR to distinguish specific and unspecific PCR products.
To sequence the gyrA primer binding sites from clinical
specimens with less efficient amplification of gyrA than the 23S
rDNA, the following primers were used: forward 5 ’-
GGATTGATTCTTCTATTGAAGAGA-3’ and reverse 5’-
AAAGGTTAGGCAGACGGCTTGGTA-3’, resulting in a 465
bp long fragment. This 465 bp fragment was sequenced (using
the forward primer) and aligned using ClustalOmega. The
difference in crossing points (Cp) between gyrA-PCR and
23SrDNA-PCR was at least 2.62 with an average of 6.84
(indicating less efficient amplification). The average differenceDecember 2020 | Volume 10 | Article 596371
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alignment of such sequences is shown below (Figure 1). The
master mix and cycler settings were equivalent, but the annealing
temperature was 55 °C instead of 58°C.
Genotype HelicoDR Assay
The Genotype HelicoDR assay (Hain Lifesciences GmbH, Nehren,
Germany) (Cambau et al., 2009) was performed according to the
manufacturer’s recommendations and assessed as interpretable if
it showed a positive hybridization signal with the conjugate and
amplification control. The assay was assessed as uninterpretable if
it showed no hybridization signal with the conjugate control or
amplification control. A specimen was reported as positive if the
three control bands HP, gyrA, and 23S were visible. A band (wild
type or mutation) was regarded as positive if the band was at least
as intense as the amplification control. However, it is stated that
the intensity of the amplification control band might vary
depending on the amount of DNA used. There was no exact
quantification of the band intensities. Therefore, reporting of the
result was dependent on the person involved. Furthermore, the
package insert states that the absence of a gyrA87Wt-band or
gyrA91Wt-band indicates the presence of resistance. If a mixed
infection occurs, at least 2 bands of either codon 87 or codon 91
can be present. The gyrA87MUT band detects N87K but only with
AAA as a codon and not AAG. Other mutations at codon 87 are
recognizable only by the absence of all gyrA87 bands. Thus, a
mixture of a wild-type sequence and a sequence with a mutation
other than AAA for codon 87 will to an incorrect report. For
codon 91, the HelicoDR test detects D91N, D91G, and D91Y.
According to the manufacturer, a single mismatch to a probe leads
to loss of the hybridization signal (Hain Lifescience:
personal communication).
Sanger Sequencing of gyrA
qPCR Products
All gyrA qPCR products were sequenced using the four forward
primers listed above. PCR products were purified with the
HighPure PCR Product Purification Kit (Sigma Aldrich), and
Sanger sequencing was performed by Microsynth (Balgach,
Switzerland) according to their recommendations. Sequences
were aligned using the ClustalOmega online tool (https://www.
ebi.ac.uk/Tools/msa/clustalo/).
Library Preparation and WGS of H. pylori
Strains
Library preparation was performed using the Qiagen® QIAseq
FX DNA Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s recommendations. Sequencing library quality
and size distribution were analyzed on a fragment analyzer
automated CE system (Advanced Analytical Technologies Inc.,
Heidelberg, Germany) according to the manufacturers’
instructions using the fragment analyzer 474 HS Next
Generation Sequencing (NGS) Kit. Sequencing libraries were
pooled in equimolar concentrations and paired-end sequenced
(2 x150 bp) on an Illumina MiSeq platform (Illumina®, San
Diego CA, USA).Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 4Raw sequencing reads (fastq) were filtered and trimmed using
the FASTQ trimmer tool of the FASTX-Toolkit (Hannon
Laboratory, Cold Spring Harbor Laboratories) applying a
threshold PHRED score of 25. To identify SNPs in
genes conferring resistance, fastq files were analyzed using
the ARIBA pipeline (Malfertheiner et al., 2017), querying
a custom-made database of gene sequences derived from
the H. pylori reference strain 26695 (NCBI reference
sequence: NC_000915.1).RESULTS
Evaluation of the In-House gyrA qPCR as
Well as qPCR for 23SrDNA in Comparison
With Hybridization-Based HelicoDR Using
Gastric Biopsies
GyrA qPCR products had a length of 248 bp. The melting
temperature (Tm) of the specific products was determined to
be between 82.0 and 84.5°C due to the high sequence diversity
(Figure 1) of clinical specimens (alignment of all positive
specimens is not shown). The results were compared to theFIGURE 1 | Alignment with ClustalOmega of a fragment of the gyrA gene for
the development of new amplification primers. Missing stars indicate
sequence variations. The sequences of the two primers “Hp gyrA-f1” and “Hp
gyrA-r“ are based on a previous publication (Fujimura et al., 2004). Numbers
(left) indicate different gastric biopsies. The reverse primers are shown in this
orientation to assign the position of the primers.December 2020 | Volume 10 | Article 596371
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this publication are those from routine diagnostics of the CLM
Dr Risch Group reported to physicians.
DNA from 142 gastric biopsy specimens (104 positive and 38
negative samples) was analyzed by gyrA qPCR followed by
Sanger sequencing, and the Genotype HelicoDR showed a
concordance of 100% regarding positive and negative results.
The best match (using NCBIBlast) for Sanger sequencing of gyrA
was always H. pylori, showing high specificity. Regarding the
determination of susceptibility or resistance, more differences
were observed between the two tests (Table 2). Amino acid
exchanges leading to resistance were found in 20 specimens with
gyrA qPCR and Genotype HelicoDR. With qPCR followed by
Sanger sequencing, 23 specimens with amino acid exchange
leading to resistance were detected. These 23 specimens
contained the following mutations: N87I 2 times, N87K 8
times, D91N 5 times, D91G 5 times, and D91Y 3 times.
HelicoDR specifically detects only N87K, D91N, D91G, and
D91Y. In one clinical specimen, the mutation N87T was
detected; however, this mutation is phenotypically susceptible
(Lauener et al., 2019). In total, there were 8 discordant results
between the two assays (Table 1). One of these specimens
showed an N87K amino acid exchange in the gyrA gene, with
an AAG codon identified by Sanger sequencing but no
hybridization signal with the Genotype HelicoDR. The lack of
a hybridization signal in the Genotype HelicoDR is because the
mutation probe for gyrA codon 87 detects only the AAA codon
for lysine. In addition, two clinical specimens were analyzed as
susceptible by the genotype HelicoDR, while amino acid
exchanges were found with gyrA qPCR combined with Sanger
sequencing. The first of these 2 clinical specimens showed a
hybridization signal with the gyr87Wt4 probe. However, the
signal was clearly weaker than the intensity from the other
probes, hinting at inefficient hybridization. GyrA qPCR and
Sanger sequencing identified an N87I exchange that should
not show a hybridization signal with the Genotype HelicoDR.
The second specimen clearly showed a D91G exchange with gyrA
qPCR and Sanger sequencing. The corresponding Genotype
HelicoDR assay showed a very weak hybridization signal below
the cut-off control and was therefore assessed as susceptible.
Notably, there were five specimens that showed weak
hybridization signals for a gyrA mutation with the Genotype
HelicoDR assay (Table 1) but did not show a mutation
with Sanger sequencing. Since there is no quantitative
measurement of the bands of the HelicoDR test and therefore
also no quantitative comparison to the control bands, the
interpretation of such results remains dependent on the
involved person.Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 5Additionally, 76 clinical specimens were analyzed as susceptible
with both tests.
Several different (silent) mutations were detected outside
codons 87 and 91 with gyrA qPCR. An exchange at codon 88
(a GCA instead of a GCG codon) caused no hybridization signal
with the gyrA87 probe in the Genotype HelicoDR (see Figure 2,
example is from different clinical specimens). According to the
instruction manual from Hain, samples lacking a hybridization
signal with the gyrA or 23S rDNA probes should be interpreted
as resistant. For this sample, the absence of the gyrA87 amino
acid exchange had no implication for levofloxacin resistanceFIGURE 2 | Hybridization assay of specimen from a gastric biopsy. Sanger
sequencing shows wild type for both codons 87 and 91 and GCA for codon
88, whereas the most frequent sequence for codon 88 is GCG. The
sequence GGCGATAA(C/T)GCAGTTTAT (codons 85 to 90 with AAC or AAT
for the most abundant codon 87) with GCA for codon 88 shows a 100%
match for only 5 entries with NCBI Blast (accession numbers CP022409.1,
CP032043.1, CP032818.1, MK348877.1, CP002332.1: database from
August 2019).TABLE 1 | Comparison of qPCR (combined with Sanger-sequencing) and
HelicoDR for gyrA using gastric biopsies that were positive for H. pylori.
HelicoDR
resistant susceptible
gyrA qPCR resistant 20 3
susceptible 5 76December 2020 | Volume 10 | Article 596371
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second specimen equivalently showed an exchange at codon 85
(a GGA instead of a GGC codon) with an additional amino acid
exchange at codon 91 (D91N), preventing false resistance
prediction. Based on these results, discrepancies must be
expected (e.g., mutation only in codons adjacent to codon87 or
91 leading to lack of bands in the hybridization test, which
should be interpreted as resistant according to package insert).
An additional clinical specimen (not included in the statistics)
confirms this statement (Figure 2).
Interestingly, there were two clinical specimens with wild-
type sequences (Sanger) at codons 87 and 91 but with amino acid
changes of E104G or V107I. Phenotypic resistance data were not
available for these two specimens. Furthermore, there were 12
specimens with mixed sequences at codons 87 or 91 (determined
with qPCR and Sanger sequencing): these were either two
different wild-type codons or wild-type and mutated codons.
Generally, 24% of gastric biopsies were reported as levofloxacin
resistant with the HelicoDR test, and the corresponding value for
qPCR and Sanger sequencing was 22%.
Moreover, the agreement between the 23S rDNA qPCR and
the Genotype HelicoDR results was assessed and showed a high
concordance (26 resistant, 74 susceptible and 4 discrepant)
(Table 2). With qPCR for 23S rDNA, one clinical specimen
was positive for Cp 37 that was reported as negative by
HelicoDR. In 23S rDNA qPCR, the 26 clarithromycin-resistantFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 6samples included 3 A2146G (11.5%) and 16 A2147G (61.5%)
mutations, and the 7 samples with heteroresistance included 1
A2146C and wild type (3.9%), 2 A2146G and wild type (7.7%),
and 4 A2147G and wild type (15.4%). The 4 discrepant samples
were reported to be susceptible by23S rDNA qPCR and showed
very weak hybridization signals in the Genotype HelicoDR. For
gyrA, the interpretation of week bands is dependent on the
experience of the involved person. Generally, 28.8% of gastric
biopsies were reported as clarithromycin resistant with the
HelicoDR test, and the corresponding value for qPCR was 25%.
Culture and susceptibility results from the 142 gastric biopsies
were not available but correlation can be reasonably inferred
based upon the data obtained from isolates.
Determination of Clarithromycin
Resistance With 23S rDNA qPCR and
WGS Using Cultured Isolates
Of the 76 H. pylori isolates, 49 (64%) were found to be
clarithromycin resistant and 27/76 (36%) susceptible by
culture-based phenotypic DST. 23S rDNA qPCR detected the
following mutations in the 49 clarithromycin-resistant H. pylori
isolates: 1 A2146C (2%), 12 A2146G (24%), 34 A2147G (70%),
and 2 H. pylori with heteroresistance (4%; wild type and A2146G
and wild type and A2147G) (Figures 3 and 4).
WGS identified the following nucleotide exchanges in the 49H.
pylori isolates: 1 A2146C (2%), 14 A2146G (31%), and 32 A2147G
(67%) (Table 3). The two H. pylori isolates with heteroresistance
identified with 23S rDNA qPCR were confirmed with WGS [one
specimen with wild type (38%) and A2146G (62%) and the second
specimen with wild type (48%) and A2147G (52%)]. BothH. pylori
isolates showed clarithromycin MICs of 256 mg/L in culture-based
phenotypic DST. As H. pylori carries two copies of the 23S
rDNA, these two samples may also contain an H. pylori gene
with heteroresistance (i.e., one wild-type and one mutated
23S rDNA).FIGURE 3 | Melting curve after qPCR for 23S rDNA. Yellow: Mixture of A2147G (52%) and wild type (48%). Quantification (%) was performed with WGS. Blue: Wild
type. Gray: A2147G. Orange: -K. The peak at 70°C can be ignored (according to the supplier).TABLE 2 | Comparison of qPCR and HelicoDR for 23S rDNA using gastric
biopsies that were positive for H. pylori.
HelicoDR
resistant susceptible
23S rDNA qPCR resistant 26 0
susceptible 4 74December 2020 | Volume 10 | Article 596371
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With gyrA qPCR Combined With Sanger
Sequencing and WGS Using Cultured
Isolates
Twenty-eight of 76 H. pylori isolates (37%) were determined to be
levofloxacin resistant and 48/76 (63%) susceptible by culture-based
phenotypic DST. Different amino acid exchanges were detected at
codons 87 and 91 by gyrAqPCRand subsequent Sanger sequencing
andWGS(Tables4 and5).Wefoundmixedsequencesat codons87
and 91 for some H. pylori isolates, with both methods (Table 5,
Figure5).Theonlydiscrepant result between gyrAqPCRcombined
with Sanger sequencing and WGS was the mixed H. pylori
population with wild-type codons 87 and 91 as well as the
following 2 amino acid exchanges: N87Y and D91N, where WGS
did not identify theD91Nexchange.Moreover, oneH.pylori isolate
was determined to be resistant by culture-based phenotypic DST
with a levofloxacinMICof 32mg/L but did not show an amino acid
exchange at codons 87 or 91.DISCUSSION
In this study, we aimed to compare different methods for the
determination of drug resistance in H. pylori. We found veryFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 7good congruence between the molecular and phenotypic results
for cultured isolates.
Phenotypic drug resistance prediction in H. pylori is less
complex than for other gram-negative bacteria, as drug
resistance is based on well-defined point mutations in specificFIGURE 4 | Melting curve after qPCR for 23S rDNA. Yellow: Mixture of A2146G (62%) and wild type (38%). Quantification (%) was performed with WGS. Blue: Wild
type. Gray: A2146G. Orange: -K. The peak at 70°C can be ignored (according to the supplier).TABLE 3 | Determination of clarithromycin resistance by phenotypic drug
susceptibility testing (DST) 23S rDNA qPCR and WGS in 76 H. pylori isolates.
Culture-based phenotypic DST
susceptible resistant
23S rDNA qPCR susceptible 27 0
resistant 0 49
WGS susceptible 27 0
resistant 0 49TABLE 4 | Determination of levofloxacin resistance by phenotypic drug
susceptibility testing (DST), gyrA qPCR combined with Sanger sequencing and
WGS in 76 H. pylori isolates.
Culture and phenotypic DST
susceptible resistant




WGS susceptible 48 1
resistant 0 27December 2020 | Volume 10 | ATABLE 5 | Identified amino acid changes in the gyrA gene of 28 levofloxacin-
resistant H. pylori strains.
Amino acid
exchanges
gyrA qPCR combined with Sanger
sequencing
WGS
N87K and wild type 12 12
N87I and wild type 1 1
N87Y and wild type – 1
D91N and wild type 3 3
D91G and wild type 4 4










N87Y and wild type
D91N and wild type
1 –rticle 591Two codons present for lysine: AAG and AAA.6371
Egli et al. H. pylori: qPCR for Molecular Resistancetarget genes and is not conferred by resistance mechanisms on
plasmids or other mobile elements (Lauener et al., 2019).
WGS and qPCR with Sanger sequencing have very good
concordance. There are slight differences regarding the
sensitivity to mixed sequences, probably because the library
preparation for WGS was performed directly from H. pylori
isolates with only 10 amplification cycles. The sensitivity of
mixed sequences is described by Folkvardsen et al. (2013), who
reported that 10% of resistance was not detectable with Sanger
sequencing. Unfortunately, there is no evidence regarding
whether a “low-abundance mutation” leads to phenotypic
resistance in H. pylori. A previous study (Redondo et al., 2018)
showed that there is a high concordance between phenotypical
and molecular resistance testing.
Due to high sequence variations in the gyrA gene even at
positions adjacent to codons 87 and 91, only SYBRGreen PCR
followed by Sanger sequencing enables good results for the fast
detection of mutations, and new primers must be added to the
qPCR if amplification efficiency of gyrA qPCR is lower than for
23SrDNA qPCR. Ailloud et al. (2019) and Estibarez et al. (2019)
reported that H.pylori is characterized by exceptional high
genetic diversity and variability. Our findings regarding the
Sanger sequencing of gyrA are consistent with this finding. We
conclude that a test with a limited set of hybridization probes of
approx. 20 bp length (“DNA strip technology” from Hain
Lifescience: (Cambau et al., 2009)), which should have a
discrimination of 1 bp, is not adequate for the detection of the
gyrA gene with very high temporal or spatial sequence diversity.
This might be the reason why very good commercial assays for
the analysis of the gyrA gene are lacking.
The fact that in one phenotypically levofloxacin-resistant H.
pylori isolate (MIC of 32 mg/L), no mutation in gyrA at codon 87 orFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 891 was detected might be a hint that other resistance mechanisms
may also occur. Smith et al. (2014) report that codons 87 and 91 are
the most significant mutation sites but not exclusive.
For RT-PCR, the time to result after DNA extraction was less
than 1 working day; for 23S rDNA, it was less than 2 h (setup and
PCR). The hands-on-time required is much less than for the
HelicoDR assay (Hain Lifescience).
Both real-time PCR and the subsequent sequencing of gyrA-
PCR-positive specimens is cost-effective and fast (Table 6). The
costs (calculated only for consumables) for both real-time PCR
methods decrease with an increased number of specimens per
run. Apparently, classical culture remains the cheapest method
compared to used molecular methods. However, the obvious
advantages of the described molecular methods for direct
detection of mutations in gastric biopsies legitimates the higher
costs. In contrast, WGS is obviously costlier than qPCRs.
Due to an increasing trend towards high primary and
secondary levofloxacin resistance in H. pylori (Zullo et al.,
2007; Boyanova et al., 2010; Cuadrado-Lavıń et al., 2012;
Saracino et al., 2012), it is encouraged to analyze the gyrA gene
in addition to performing qPCR for 23S rDNA. This
recommendation is supported by the results of gastric biopsies
(direct detection) with 22%–24% resistance for levofloxacin and
25%–29% for clarithromycin (the range is due to the slight
difference between the two test procedures).
Since the gyrA gene is a single-copy gene (Tomb et al., 1997),
mixed sequences are always mixed infections. Sanger sequencing
showed were 4 mixed infections (5.2%) among the 76 cultured
isolates based on the sequence diversity of the gyrA gene.
A review article from African studies (Jaka et al., 2018)
declares a very broad percentage of clarithromycin resistance
(between 0% and 100%) with an overall resistance of 29.2%.FIGURE 5 | Chromatogram of Sanger sequencing. Red bar marks codon 87. WGS: Position 87, AAG (70%) and AAA (30%). AAA was below the cutoff for WGS
(8x detected, cutoff was 10x). AAG and AAA both encode Lys.TABLE 6 | Comparison of the assay characteristics of phenotypic drug susceptibility testing (DST), qPCR, and melting curve analysis, Sanger sequencing and whole-
genome sequencing (WGS).
H. pylori culture and
phenotypic DST
qPCR(23S rDNA and gyrA) Sanger sequencing
(gyrA from qPCR)
WGS
Starting material clinical specimen clinical specimen – H. pylori culture
Time to result 7 to 14 days <4 h 1 day 2 days
Costs (EUR) 20.- 5.- DNA isolation
max 20.- qPCR
20.- 150.-December 2020 | Volume 10For both qPCR methods, costs are reduced for larger series. Costs (EUR) are per sample (culture or biopsy).| Article 596371
Egli et al. H. pylori: qPCR for Molecular ResistanceAdditionally, this review declares a quinolone resistance of 0% to
32% with the overall resistance of 17.4% (Jaka et al., 2018).
Another review (Savoldi et al., 2018) declares in European region
an overall clarithromycin resistance of 32% and levofloxacin
resistance of 14%. Another study (Megraud et al., 2013) with data
in Europe declares a clarithromycin resistance of 17.5% and
levofloxacin resistance of 14.1%, however with generally lower
percentages in Northern European countries. Our data show,
that the clarithromycin resistance, which was detected directly
from gastric biopsies, remains high as previously found in one of
the two reviews. However, for levofloxacin resistance (direct
detection from gastric biopsies as well), our data shows an
increased percentage of levofloxacin resistant H. pylori
infections. Since the usage of qPCRs for 23SrDNA are
prevailing (i.e., without analysis of gyrA (Bénéjat et al., 2018)),
it can be suspected that prescription of levofloxacin for those
numerous cases with detected clarithromycin resistance might
select gyrA mutations (Marques et al., 2020). qPCRs are proven
to be of clinical relevance to avoid difficulties of culture (Bénéjat
et al., 2018). The parallel testing (qPCR for 23SrDNA and gyrA)
enables the opportunity for adequate antibiotic treatment, since
also other antibiotic classes can be used for treatment (Lauener
et al., 2019) even for those cases with dual resistance
(clarithromycin and levofloxacin).CONCLUSION
Since the successful isolation and cultivation of H. pylori from
gastric biopsy specimens is a challenging task hampered by a
number of technical factors and is long-lasting as well, it is
beneficial for the timely treatment of the patient to have an
adequate molecular test which enables resistance testing
directly from gastric biopsies. Application of qPCR is
meanwhile well-established and results therefore in novel
diagnostic tools. In particular, the novel qPCR (23SrDNA and
gyrA) and (Sanger) sequencing (gyrA) can overcome
disadvantages of cultures and should be applied for the
detection of H. pylori in gastric biopsies. The two evaluated
qPCR tests for 23S rDNA and gyrA are much faster than
culture, sensitive, specific, include carry-over prevention and
were extensively, which includes cultured isolates as well as
direct detection from gastric biopsies. Due to the high
percentage of both levofloxacin and clarithromycin resistance,Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 9which was directly detected in gastric biopsies (both between
22% and 29%), both targets have to be analyzed in parallel.
Furthermore, due to high sequence variations in the gyrA gene,
SYBRGreen PCR followed by Sanger sequencing is currently
the best and fastest available molecular method. WGS strongly
supports results of both qPCR using cultured isolates. For the
direct detection of H. pylori in gastric biopsies, WGS has the
limitation that the strong abundance of human DNA might
reduce sensitivity of the two relevant targets.DATA AVAILABILITY STATEMENT
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